TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17878467
Drug: Bronchodilators (beta(2)-agonists
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators (beta(2)-agonists and anticholinergics), including once-a-day preparations and combination products with inhaled steroids.
Study: 17878467
Drug: Anti-inflammatory agents
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory agents under development for COPD.
Study: 17878467
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatments.
Study: 11907489
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 0.1% 8-methoxypsoralen cream
Study: 11907489
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 3 mg/L 8-methoxypsoralen bath
Study: 11907489
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 0.6 or 1 mg/kg 8-methoxypsoralen
Study: 7842186
Drug: Uniphyl (theophylline),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (theophylline), once daily
Study: 7842186
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200 micrograms four times per day)
Study: 7842186
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Uniphyl and salbutamol
Study: 365289
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatment plus intermittent positive-pressure ventilation (IPPV)
Study: 31050982
Drug: Extracorporeal Magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Magnetic Innervation (ExMI) therapy
Study: 29349982
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml physiological saline (Group A)
Study: 29349982
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml tranexamic acid and 10 ml physiological saline (Group B)
Study: 29349982
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml physiological saline (Group C)
Study: 29349982
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml tranexamic acid and 10 ml physiological saline (Group D)
Study: 26849923
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (Group A)
Study: 26849923
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil (MMF) (Group B)
Study: 9500317
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin
Study: 19566116
Drug: Standard-dose cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporin
Study: 12647600
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/d; n = 5,170)
Study: 10579150
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg with bupropion SR 300 mg (two 150 mg tablets)
Study: 10579150
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg alone (two 150 mg tablets)
Study: 1460158
Drug: Emotionally focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotionally focused therapy (EFT)
Study: 1886157
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy (2 or 5 years)
Study: 2189951
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjuvant endocrine therapy)
Study: 6229567
Drug: 25% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% reduction in lithium dosage
Study: 6229567
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in lithium dosage
Study: 6229567
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of lithium (control)
Study: 27084661
Drug: Proton Beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Beam Radiation Therapy
Study: 25438482
Drug: NitroSense Derma
Normalized name: Derma Gran
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NitroSense Derma Protect patch (24 mg, releasing 9 nmol/cm2/min of nitric oxide for 3 hours every other day for 3 weeks)
Study: 25438482
Drug: NitroSense Derma
Normalized name: Derma Gran
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NitroSense Derma Protect patch
Study: 22097612
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg/d
Study: 17615018
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - Brief intervention by dental professionals providing feedback on oral symptoms and dental treatments relevant to smoking.
Study: 11956262
Drug: Oxaliplatin 60
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 60 mg/m² on days 1, 8, and 15 repeated every 4 weeks (group 1; n = 16)
Study: 11956262
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m² on days 1 and 15 of a 4-week cycle (group 2; n = 16)
Study: 11956262
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with oxaliplatin
Study: 10450425
Drug: Chemoprophylaxis alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis alone or in combination with iron
Study: 28625512
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen (HDER)
Study: 28625512
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen (LDER)
Study: 31687762
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (HDER, LDER, Warfarin)
Study: 28597176
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - Pharmacist monitoring with CARAT questionnaire every 2 weeks and counselling on disease management, ICS adherence, and inhalation technique
Study: 22987022
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg
Study: 19573556
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (250 mg) plus Vitamin B12 (100 microg), folic acid (300 microg), Vitamin B6 (12.5 mg) and l‐arginine (100 mg) daily for 1 year
Study: 7957512
Drug: M(r) 2264
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: M(r) 2264 Cl 2 x 5 mg i.v.
Study: 7957512
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 x 10 mg i.v.
Study: 3054373
Drug: Induction chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy, surgery, postoperative radiotherapy
Study: 3054373
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (surgery and postoperative radiotherapy)
Study: 22182309
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (all extra contacts)
Study: 24002499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiviral treatment)
Study: 9818712
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fexofenadine HCl
Study: 9818712
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fexofenadine HCl
Study: 9818712
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg fexofenadine HCl
Study: 9818712
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg fexofenadine HCl
Study: 7646652
Drug: Systemic flurbiprofen;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic flurbiprofen; appropriate doses not specified
Study: 2575765
Drug: Cavain (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavain (2 x 200 mg daily)
Study: 30768
Drug: Lorazepam 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 3.0 mg b.i.d. for 4 weeks
Study: 11557486
Drug: Ethambutol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol (15 mg/kg of body weight) administered orally once daily to subjects with AIDS and healthy volunteers.
Study: 29974725
Drug: Phytotherapic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapic combination of L-Methionine, Hibiscus sabdariffa, and Boswellia serrata (1 tablet in the morning and 1 tablet in the evening for 7 days)
Study: 29974725
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term antibiotic treatment according to international guidelines recommendations
Study: 25620034
Drug: Breathing exercises
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing exercises with positive expiratory pressure (10-15 cmH2O), 30 slow deep breaths twice a day for 2 months
Study: 22744417
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mATPase histochemistry and MHC immunohistochemistry
Study: 17403707
Drug: Alfentanil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil doses of 15, 30, 45 microg kg‐1
Study: 7657272
Drug: 12-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month treatment starting with 6 MU three times a week, decreasing dose based on serum ALT (Group A: 59 cases)
Study: 7657272
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 3 MU three times a week for 12 months (Group B: 61 cases)
Study: 7657272
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 6 MU three times a week for 6 months (Group C: 54 cases)
Study: 2503945
Drug: Sublingual Nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Nitroglycerin
Study: 2503945
Drug: Sublingual Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual Nifedipine
Study: 178838
Drug: Mithramycin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mithramycin at a dose of 25 mug/kg/day for 21 days
Study: 28333342
Drug: Faropenem (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Study: 28333342
Drug: Rifampicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (10 mg/kg)
Study: 28333342
Drug: Rifampicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (10 mg/kg) + Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Study: 23862647
Drug: 120 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/kg weekly intravenous alpha1-PI
Study: 23862647
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg weekly intravenous alpha1-PI
Study: 12207105
Drug: Computer-guided behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided behaviour therapy (BT)
Study: 12207105
Drug: Clinician-guided behaviour
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided behaviour therapy (BT)
Study: 10483277
Drug: Palliative accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative accelerated irradiation (PAIR) with a total dose of 32 Gy (2 x 2 Gy/d)
Study: 10483277
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with a total dose of 60 Gy (K60)
Study: 10483277
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (PAIR and conventional)
Study: 8552931
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sustained-release melatonin
Study: 8552931
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg fast-release melatonin
Study: 8552931
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sustained-release melatonin (2-month treatment)
Study: 1793876
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin per day
Study: 1793876
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin or antiplatelet agents
Study: 7011010
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus six cycles of adjuvant chemotherapy
Study: 7011010
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone or radiation therapy plus chemotherapy
Study: 29209867
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied at 780 nm, masseter and temporal=5 J/cm2 (20 mW-0.5 W/cm2), TMJ area=7.5 J/cm2 (30 mW-0.8 W/cm2), eight sessions, twice a week.
Study: 11800440
Drug: Without treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without treatment (WT)
Study: 29209867
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with low levels of anxiety, salivary cortisol below 10 ng/ml, and with contraceptive use
Study: 26471311
Drug: 100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU oral D3 supplementation
Study: 19083662
Drug: Spray and
Normalized name: Spray and Stretch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray and stretch treatment (vapocoolant blend of pentafluoropropane and tetrafluoroethane)
Study: 19083662
Drug: Spray and
Normalized name: Spray and Stretch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray and stretch treatment
Study: 3372910
Drug: 2 units
Normalized name: Afrezza, 12 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 units of intravenous glucagon
Study: 3372910
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of saline (placebo)
Study: 27855097
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment at the original dose plus intravenous iron dextran 200 mg every 3 weeks (Q3W) for 15 weeks
Study: 27855097
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment at the original dose plus intravenous iron dextran 100 mg, twice a week for 5 weeks
Study: 27855097
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the EPO dose without preplanned iron supplementation
Study: 22836063
Drug: Concomitant accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant accelerated boost (CB: once per day, 3 days per week, and twice per day, 2 days per week)
Study: 20390354
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel preparation (BP)
Study: 20390354
Drug: Surgery without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery without bowel preparation (BP)
Study: 16888454
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (20 g.d(‐1) for 7 d then 5 g.d(‐1) for 4‐7 d)
Study: 333852
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg nalbuphine
Study: 333852
Drug: 0.14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg nalbuphine
Study: 333852
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg pentazocine
Study: 333852
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg pentazocine
Study: 6759060
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (160 mg once daily)
Study: 6759060
Drug: Sustained-release clonidine
Normalized name: clonidine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release clonidine (0.25 mg once daily)
Study: 29343076
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin 40 mg daily for 1 day before to 3 days after contrast administration
Study: 29343076
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose atorvastatin 10 mg daily for 1 day before to 3 days after contrast administration
Study: 19028044
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg once in the morning for 7 days post-operation)
Study: 19028044
Drug: Standard pre-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pre- and postoperative therapy (control group B)
Study: 17574951
Drug: Neck muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck muscle endurance (NME) treatment for patients with NP
Study: 17574951
Drug: Neck muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck muscle endurance (NME) treatment for patients with ACDF
Study: 11933130
Drug: Pycnogenol (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (360 mg per day)
Study: 11933130
Drug: Venostasin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venostasin (600 mg per day)
Study: 9862573
Drug: Linomide 5
Normalized name: cupric oxide 1.5 MG / folic acid 0.5 MG / niacinamide 750 MG / zinc oxide 25 MG [Nicomide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide 5 mg or 10 mg p.o. daily for 2 weeks
Study: 9862573
Drug: Alpha‐interferon added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐interferon added at 3 MU s.c. three times weekly, escalating by 3 MU per week up to 12 MU
Study: 9862573
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Linomide and alpha‐interferon
Study: 9862573
Drug: Linomide 5
Normalized name: cupric oxide 1.5 MG / folic acid 0.5 MG / niacinamide 750 MG / zinc oxide 25 MG [Nicomide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide 5 mg for 2 weeks
Study: 28810837
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response to treatment
Study: 8770850
Drug: tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tissue plasminogen activator (t-PA) given in an accelerated dosing regimen
Study: 11097130
Drug: No reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reperfusion therapy
Study: 20551
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg BS 100‐141
Study: 20551
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg BS 100‐141
Study: 20551
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg BS 100‐141 (crossover study)
Study: 20551
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg BS 100‐141 (crossover study)
Study: 20551
Drug: 0.30 mg
Normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg clonidine (crossover study)
Study: 19708803
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg three times daily (TID)
Study: 17561929
Drug: levocetirizine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocetirizine 0.125 mg/kg
Study: 11897984
Drug: High bronchodilator
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bronchodilator reversibility
Study: 30929225
Drug: Medical exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical exercise therapy
Study: 8582540
Drug: Darglitazone 25
Normalized name: alogliptin 25 MG / pioglitazone 30 MG [Oseni]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darglitazone 25 mg once a day for 14 days
Study: 355602
Drug: Baclofen (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (mean dose 45 mg daily)
Study: 31870811
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients (BMI ≥30 kg/m2) in the MSK immunotherapy cohort
Study: 30741705
Drug: Cognitive orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive orientation to daily occupational performance (CO‐OP)
Study: 25344807
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tenofovir/emtricitabine/rilpivirine